Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Summary

This is a randomized, open-label, parallel-group multi-center study of Phase 3 study to assess the efficacy and safety of KN035 compared to standard of care (SOC) Gemcitabine-based chemotherapies in the treatment of participants with previously untreated locally advanced or metastatic biliary tract cancer. The primary hypothesis of this study is that participants will have a longer overall Survival (OS) when treated with combined therapy than SOC.

Timeline

Start

2018-04-16

Primary completion

2024-09-10

Completion

2026-12-31

Drugs

Indications